From The Stage

Ligand-Binding Assay Optimization, Part 1: Critical Attributes of Platforms Used

Dr. Afshin Safavi
Posted by Dr. Afshin Safavi / / Bioanalytical Platforms

Consistent discussion and improvement upon the standard practices of bioanalytical laboratories is critical to improving the work we do supporting innovative biologics development in the long-term. One of the rapidly advancing areas that is being regularly discussed in the industry is the evolution of ligand-binding assay (LBA) platforms. In this blog, I will summarize best practices and characteristics associated with LBA platforms as well as the features these platforms absolutely need to enable scientists to respond to industry pressures that drive demand for increasingly complex bioanalysis, condensed timelines, and continued…

Key Takeaways from 2018’s AAPS PharmSci 360

Dr. Dominique Gouty
Posted by Dr. Dominique Gouty / / BioAgilytix Insight, Industry Update

Our team had the opportunity to both attend and present at a number of content-rich sessions during AAPS’ 2018 PharmSci 360 event. These conversations will have a direct impact on our own work moving forward, and we wanted to summarize and share a few of the key takeaways we found most interesting and valuable.